# Alternate-Day Buprenorphine Administration. Phase I - 3

> **NCT00000221** · PHASE1 · COMPLETED · sponsor: **National Institute on Drug Abuse (NIDA)**

## Conditions studied

- Opioid-Related Disorders

## Interventions

- **DRUG:** Buprenorphine

## Key facts

- **NCT ID:** NCT00000221
- **Lead sponsor:** National Institute on Drug Abuse (NIDA)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1992-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000221, "Alternate-Day Buprenorphine Administration. Phase I - 3". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00000221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*